BGI Genomics to Inject 149 Million Yuan in Equity Investment Fund
BGI Genomics (SHE:300676) invested 149 million yuan in an equity investment fund, according to a Tuesday disclosure on the Shenzhen Stock Exchange.
The fund, Shaoxing Meiyue Medical Industry Equity Investment Partnership (Limited Partnership), will raise a capital of 500 million yuan.
The Chinese genomics services provider will own 29.8% of the fund's capital.
The other partners, Keqiao Jinkai New Materials, will own 70% of the fund after injecting 350 million yuan, while Kemei Health Management (Shaoxing Keqiao) will own the remaining 0.2% after injecting 1 million yuan.
Price (RMB): ¥34.76, Change: ¥-0.030, Percent Change: -0.09%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。